Skip To Main Content
Barbara Burtness on Muck Rack

Barbara Burtness

As seen in: Nature, Wiley Online Library, MDPI, JAMA Oncology, The Lancet, Healio, HemOnc Today, Newswise, NewsBreak, Journal of Clinical Oncology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Choosing Between Approved Frontline Metastatic Pancreatic Cancer Regimens

|
By Timmy Nguyen, Raji Shameem, Barbara Burtness
| ONCOLOGY journal Verified
With 3 regimens now approved for the frontline treatment of metastatic pancreatic cancer, oncologists face an increasingly complex decision about which combination to use first, and how that choice affects a patient's options down the line. NALIRIFOX (liposomal irinotecan [Onivyde], oxaliplatin, 5-fluorouracil [5-FU], and leucovorin) was evaluated against gemcitabine plus nab-paclitaxel (Abraxane) in the phase 3 NAPOLI-3 trial (NCT04083235).
Open in Who Shared Issue with article?

Safusidenib Earns FDA Fast Track Designation for IDH1-Mutant Glioma

|
By Tim Cortese, Russ Conroy, Barbara Burtness
| ONCOLOGY journal Verified
The FDA has granted fast track designation to safusidenib, an investigational, oral, brain-penetrant selective inhibitor of mutant IDH1, for the treatment of patients with IDH1-mutant glioma, according to a news release from the company.1 The designation is supported by favorable data from safusidenib in this patient population.
Open in Who Shared Issue with article?

Belzutifan Combo Improves Disease Control Vs Cabozantinib in Advanced RCC

|
By Roman Fabbricatore, Russ Conroy, Barbara Burtness
| ONCOLOGY journal Verified
Results from the phase 3 LITESPARK-011 trial (NCT04586231) showed that belzutifan (Welireg) plus lenvatinib (Lenvima) significantly improved disease control compared with cabozantinib (Cabometyx) in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC), according to a news release from the Vall d'Hebron Institute of Oncology (VHIO).¹ What did the phase 3 LITESPARK-011 trial show?
Open in Who Shared Issue with article?
See all 46 licensed articles (75 Total)